Acknowledgments
NSCLC, HCC,, tumor, HL, Hodgkin lymphoma, HNC, Tumors, PD, RCC, Cancer
NON-SMALL CELL LUNG CANCER, ADVERSE EVENT, TUMOR, ADVERSE EVENTS, DISEASE, ANAPLASTIC THYROID CANCER, NASOPHARYNGEAL CARCINOMA, TUMORS, HEAD AND NECK CANCER, ONCOLOGY, NSCLC, HEPATOCARCINOMA, RENAL CELL CARCINOMA, DUODENAL CARCINOMA, RCC, CANCER
The authors are grateful to the patients, families, investigators and study teams who participated in CAP study. Liposomal irinotecan, camrelizumab and apatinib were provided by Jiangsu Hengrui Pharmaceuticals Co., Ltd.ATC, anaplastic thyroid cancer; CBR, clinical benefit rate; CI, confidence interval; DA, duodenal carcinoma; DCR, disease control rate; DoR, duration of response; ECOG, Eastern Cooperative Oncology Group; EPR, enhanced permeability and retention; FAS, full analysis set; HCC, hepatocarcinoma; HL, Hodgkin lymphoma; HNC, head and neck cancer; irAEs, immune-related adverse events; IV, intravenously; NCI CTCEA, National Cancer Institute Common Terminology Criteria for Adverse Events; NE, not evaluable; NPC, nasopharyngeal carcinoma; NPs, nanoparticles; NR, not reached; NSCLC, non-small cell lung cancer; ORR, objective response rate; OS, overall survival; PD, progressive disease; PFS, progression-free survival; RCC, renal cell carcinoma; RECIST 1.1, Response Evaluation Criteria in Solid Tumors version 1.1; SAEs, serious adverse events; SBRT, stereotactic body radiotherapy; SD, stable disease; TME, tumor microenvironment; TRAEs, Treatment-related adverse events; TTR, time to response.